07:50 AM EDT, 10/17/2024 (MT Newswires) -- Amicus Therapeutics ( FOLD ) said Thursday that it agreed to grant Teva Pharmaceuticals (TEVA) a license to market its generic version of Amicus' treatment Galafold in the US starting in early 2037, as a settlement for a patent litigation against Teva.

Amicus previously filed a complaint relating to Teva's abbreviated new drug application to market its generic version of Galafold prior to the expiration of the applicable patents.